The aVaxziPen needle-free vaccine yielded positive data


aVaxziPen, a biotechnology company developing a new needleless vaccine delivery platform, presented its data at the World Vaccine Congress (WVC) in Washington, USA, recently.

The company presented a poster entitled, “Delivery of a needleless injectable solid-dose vaccine produces an equivalent immune response to different antigens and animal models.”

The company says the immunogenicity data from its four in vivo models reinforces the value of its needle-free solid-dose vaccine platform as a new way to effectively deliver tetanus, anthrax, influenza, and peanut allergy vaccines.

As well as increasing ease of administration and accessibility, this technology offers the potential to reduce vaccine hesitancy related to needle phobia.

The solid-dose formulation technology is designed to improve the thermal stability of conventional vaccines, which can reduce cold chain logistics demands during distribution.

aVaxziPen transforms vaccine delivery

Keith Howard, CSO of aVaxziPen, said: “With our needle-free technology, we are on a mission to transform vaccine delivery for the benefit of people around the world. Our new solid-dose formulation technology coupled with our ‘click-and-send’ pen device has the potential to increase the accessibility and cost-effectiveness of every day vaccines. This new in-vivo data, presented in Washington at the World Vaccine Congress, shows how our technology produces comparable immune responses to multiple vaccines in a needleless presentation.”

In a poster presented at WVC, in vivo data show equivalent immunogenicity for the aVaxziPen needle-free solid-dose vaccine compared to existing injectable vaccine presentations, in four examples: attenuated recombinant vaccinia virus expressing the peanut allergen; tetanus toxoid vaccine with alum adjuvant; recombinant protective antigen anthrax vaccine; and recombinant H7 influenza vaccine.

The company has completed building a production line using insulator technology that is capable of producing sterile products for clinical trials in humans.



Source link

Related Articles

Back to top button